Erchonia Secures U.S. Patent for New Laser Technology to Treat Nail Fungus

Share Article

Erchonia today announces the company has secured U.S. Patent No. 8,814,924 entitled, “Fungal infection therapy device with low level laser” for a portable low level laser device to treat onychomycosis, commonly known as nail fungus.

Erchonia

Securing this patent is the important first step in our plan to launch the technology to the U.S. market

Erchonia, the global leader in low level laser healthcare applications, today announces the company has secured U.S. Patent No. 8,814,924 entitled, “Fungal infection therapy device with low level laser” for a portable low level laser device to treat onychomycosis, commonly known as nail fungus.

Erchonia’s portable laser device produces a laser beam that may be rotated and scanned to apply laser energy to a targeted area or may be automated to provide a treatment regimen to a patient's hands or feet that are infected by onychomycosis. The laser device is activated and laser energy is scanned across the infected area of the patient's first hand or foot. The laser energy may be applied for about 10 minutes to about 30 minutes on the patient's first hand or foot and then the application may be repeated on another infected appendage if desired.

Traditionally, nail fungus has been treated with prescription oral antifungal medication, with the potential for liver toxicity issues, or with ineffective, over-the-counter, topical creams. In contrast, Erchonia’s low level laser therapy is administered non-invasively and efficiently. Using low level laser light, it eradicates fungus from nails—without pain and without adverse affects. Plus, the Erchonia laser radiates all ten toes at the same time so even if a nail is infected under the surface, the laser therapy will eliminate the fungus.

“Erchonia is already offering this technology to patients in Europe, but securing this patent is the important first step in our plan to launch the technology to the U.S. market,” comments Charlie Shanks, vice president of Erchonia. “We have also submitted our clinical data to the FDA.”

For more information, please visit http://www.erchonia.com.

About Erchonia
Erchonia is the global leader in low level laser healthcare applications. Over the last 15 years Erchonia has been conducting research and development with the world’s leading physicians to advance the science of low level lasers. Prior to market introduction, all Erchonia lasers are proven safe and effective through independent clinical trials. Currently thousands of Erchonia’s lasers are used daily to reduce body fat and cellulite, eliminate pain, and treat acne. For additional information, visit http://www.erchonia.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Katie Cycan
Visit website